T wo landmark trials conducted >30 years ago provided scientific evidence that, under very specific circumstances, long-term oxygen therapy (LTOT) may prolong life (1, 2) . These two trials targeted patients with chronic obstructive pulmonary disease (COPD) and severe daytime hypoxemia documented using direct arterial blood gas measurement. A total of 290 patients were randomly assigned: 87 in the British trial (1) and 203 in the American trial (2) . Both studies focused on life prolongation rather than quality of life, and cost effectiveness was not an issue at the time. Thereafter, oxygen therapy became standard of care in COPD, and confirmatory trials would now be considered unethical by many clinicians and scientists. New indications of oxygen therapy in COPD (such as nocturnal oxygen therapy in patients with isolated nocturnal oxygen desaturation, or ambulatory oxygen to correct exercise-induced desaturation) have since emerged. Oxygen therapy has also gained widespread acceptance by official organizations for the management of many other chronic cardiorespiratory conditions complicated by severe hypoxemia, even if proof of efficacy is lacking (3) (4) (5) . In addition, oxygen is often prescribed to alleviate dyspnea in patients receiving palliative care.
Home oxygen therapy is expensive. For instance, in the Canadian cohort of the Confronting COPD Survey (n=401; mean age 63 years; 51% female; 35 [8. 7%] on LTOT), oxygen therapy accounted for 17% of the entire annual direct costs of COPD care (6) . Unfortunately, inappropriate prescriptions of home oxygen are not unusual (7) . In this regard, the American Thoracic Society and the American College of Chest Physicians identified the prescription of supplemental home oxygen following hospitalization for an acute illness as one of the top five tests or interventions that are commonly and incorrectly used at great expense in adult pulmonary medicine (8) .
In Canada, provinces and territories are responsible for delivering health care services, guided by the provisions of the Canada Health Act. Although medical insurance is generally universal, we realized, in our planning of a national trial of nocturnal oxygen therapy in COPD (the INOX trial; ClinicalTrials.gov NCT01044628), that significant differences exist in the provision of home oxygen therapy across the country. These differences are created and maintained within home oxygen programs by province-specific terms of reference defining and governing eligibility to equipment, allied services and reimbursement.
From this observation, we undertook the present study with the primary objective of systematically comparing the terms of reference to oxygen therapy across Canada, with a focus on the clinical inclusion criteria to the programs. Our secondary objective was to confront these eligibility criteria to the current national COPD clinical practice guidelines and to the best evidence from the literature. We also sought to describe the terms of reimbursement across jurisdictions. 
BACKGROUND:
In Canada, although medical insurance is generally universal, significant differences exist in the provision of home oxygen therapy across the country. OBJECTIVE: To systematically compare the terms of reference for home oxygen across Canada, with a focus on the clinical inclusion criteria to the programs.
METHODS:
The authors searched the terms of reference of the 10 Canadian provinces and three territories, focusing on general eligibility criteria for home oxygen (including blood gas criteria, and eligibility criteria for ambulatory and nocturnal oxygen), and compared the eligibility criteria to the widely accepted criteria of the Nocturnal Oxygen Therapy Trial (NOTT) trial, the clinical recommendations of the Canadian Thoracic Society and the results of Cochrane reviews.
RESULTS:
The terms of reference for nine provinces were retrieved. All jurisdictions have similar criteria for long-term oxygen therapy, with slight differences in the thresholds of prescription and the clinical criteria defining 'pulmonary hypertension' or 'cor pulmonale'. The use of oxyhemoglobin saturation as a criterion for funding is inconsistent. All nine provinces fund nocturnal oxygen, all with different clinical criteria. Funding for portable oxygen widely varies across provinces, whether the ambulatory equipment is offered to patients on long-term oxygen therapy or to those who have isolated exercise-induced desaturation. The terms of reimbursement are very heterogeneous. CONCLUSIONS: Heterogeneity exists in the criteria for eligibility to home oxygen programs and funding across Canada. Terms of prescription and reimbursement of oxygen are not necessarily supported by available evidence from the current literature in several Canadian jurisdictions. 
METHODS

Terms of reference: inclusion and retrieval
The authors consulted the websites of the ministries or divisions of health for the document reporting on the terms of reference to oxygen therapy of the 10 Canadian provinces and three territories. For validation purposes, whenever necessary, or when no document was available on the Internet, the provincial or territorial division responsible for home care programs was directly contacted. As a last resort, a respirologist involved in the care of patients with COPD was contacted to obtain information on the provision of home oxygen in his/her province. To be considered, the documents had to be officially endorsed by the provincial or federal governments. Prescription forms or clinical guides from private oxygen suppliers were, therefore, excluded.
Data extraction
From each document, two reviewers (YL and SB) extracted the following information: date of publication; who is accredited to prescribe oxygen; the eligible diagnoses (including COPD and other cardiorespiratory conditions); general eligibility criteria for home oxygen (including blood gas criteria, and eligibility criteria to ambulatory and nocturnal oxygen); eligibility for oxygen therapy in palliative care; whether current smokers are eligible to home oxygen; and the terms of reimbursement.
Comparison with the current Canadian recommendations and international literature
General eligibility criteria for LTOT in COPD were compared with the usual and widely accepted criteria of the Nocturnal Oxygen Therapy Trial (NOTT): in a period of clinical stability, partial pressure of oxygen in arterial blood (PaO 2 ) ≤55 mmHg; or PaO 2 ≤59 mmHg with clinical evidence of at least one of the following: peripheral edema (cor pulmonale); hematocrit ≥55%; or right ventricular hypertrophy (P pulmonale on electrocardiogram: 3 mm in leads II, III, aVF) (2). The eligibility criteria for nocturnal and ambulatory oxygen were also correlated with the clinical recommendations put forward by the Canadian Thoracic Society (CTS) in its latest practice guidelines targeting COPD (9) . Although this document was published by an official organization, it has no authority on the provision or reimbursement of oxygen in the country. For indications and conditions other than LTOT in COPD, the eligibility criteria for home oxygen programs were compared with the results of Cochrane reviews. In this comparison, investigation of the use of oxygen was limited to two clinical conditions that were selected a priori: interstitial lung diseases (10) and palliative care (11) .
Analysis
The present study was descriptive only. Statistics were limited to proportions. No statistical comparisons were involved.
RESULTS
Terms of reference (Table 1)
The terms of reference for nine of the 10 Canadian provinces were retrieved. There is no home oxygen program in Newfoundland, Yukon, the Northwest Territories (Dr Nigel Duguid, respirologist, St John's, Newfoundland; Mrs Heather Alton, Manager, Community Care, Yukon Health and Social Services; Mrs Kim Riles, Director, Territorial Health Services, Department of Health and Social Services, Government of Northwest Territories; all personal communications) and, presumably, Nunavut (because no one at the Department of Health and Social Services in Iqaluit could be contacted). With the only exception of the document from Prince Edward Island, whose date of publication was not clearly specified, all terms of reference were published between 2007 and 2014. The extent of the documents ranged from a simple application form containing the eligibility criteria (eg, Prince Edward Island) to comprehensive guides detailing specific criteria to home oxygen therapy, terms of reimbursement and responsibilities of private equipment suppliers (eg, Alberta, Manitoba, Ontario, Quebec and Nova Scotia).
Comparison among terms of reference Prescriber:
In all nine provincial terms of reference, home oxygen can be prescribed by physicians. In two provinces (Manitoba and Nova Scotia), the indication of oxygen must be confirmed by physicians designated by regional or provincial authorities. In British Columbia, Saskatchewan and Ontario, nurse practitioners can also prescribe oxygen. Eligibility criteria: Details regarding the criteria of funding for longterm, nocturnal and portable oxygen are provided in Table 2 . In seven of the nine documents, general criteria apply to any health condition that may benefit from oxygen therapy, without distinction between COPD and other cardiorespiratory diagnoses. In Quebec, specific criteria exist for 10 cardiorespiratory different diagnoses including COPD. In Alberta, in addition to general eligibility criteria, special recommendations are provided for hypoventilation syndrome on longterm ventilatory support and for palliative cardiac patients.
All organizations have similar criteria for LTOT. However, slight differences exist in the thresholds of prescriptions and in the clinical criteria defining 'pulmonary hypertension' or 'cor pulmonale' when PaO 2 is in the range of 56 mmHg to 60 mmHg. The use of oxyhemoglobin saturation as a criterion for funding is inconsistent among provinces. Quebec, Nova Scotia and Prince Edward Island are the only three provinces that do not fund home oxygen on the basis of oxygen saturation alone. The notions of "clinical stability", "optimal therapy" and/or "reassessment" if the initial prescription of oxygen is made during the course of an exacerbation are included in the nine documents. All nine provinces fund nocturnal oxygen, all with different clinical criteria. Finally, funding for portable oxygen widely varies across provinces, whether the ambulatory equipment is offered to patients on LTOT or to those who have isolated exerciseinduced desaturation. Palliative oxygen (Table 3) : Even if palliative oxygen is provided in all nine provinces, the criteria for eligibility are heterogeneous. Clinical indications, saturation criteria, period of funding and conditions of prescription renewal are all different. In Saskatchewan, coverage even includes portable oxygen cylinders. Oxygen in current smokers (Table 4) : Saskatchewan is the only province where no specific instruction is given when oxygen is prescribed to current smokers. In all eight other documents, restrictions to home oxygen therapy in smokers are more or less directive. Nova Scotia has the strictest restrictions.
Comparison with current Canadian recommendations and the international literature
In all nine documents, criteria for LTOT are based on the inclusion criteria of the NOTT trial (2), which are also supported by the CTS (9). Slight differences exist in the thresholds of prescriptions and the NOTT's clinical criteria defining pulmonary hypertension or cor pulmonale when PaO 2 is in the range of 56 mmHg to 60 mmHg. Although nocturnal and portable oxygen is funded everywhere, the CTS does not support the use of nocturnal oxygen in patients with isolated nocturnal desaturation, or the provision of ambulatory oxygen to patients with COPD.
In the nine terms of reference, oxygen for patients with interstitial disease is based on the same general eligibility criteria as those with COPD. In Cochrane reviews, the assumption that home oxygen therapy has a beneficial survival effect in patients with interstitial lung disease has not been demonstrated in the single randomized controlled trial identified by Crockett et al (10) . Similarly, although palliative oxygen is funded everywhere, in cancer patients, it failed to demonstrate a beneficial effect over air breathing, although this conclusion was limited by the small volume of research studies available for inclusion (11) .
Terms of reimbursement
Patients receive full funding in five provinces (British Columbia, Alberta, Manitoba, Saskatchewan and Quebec). In Ontario, full funding is provided for patients ≥65 years of age; with few exceptions, 75% of the monthly rate is reimbursed for those <65 years of age. In New Brunswick, an amount of $100 per month is reimbursed for the concentrator for individuals ≥65 years of age; palliative oxygen is funded on a discretionary basis, and portable cylinders are provided for medical appointments only. In Nova Scotia, the funding program will pay approved vendors for the services provided in accordance with a detailed schedule (eg, $200 per client per month for standard concentrator and related supplies, and $18 per portable cylinder). Similarly, in Prince Edward Island, financial assistance is up to 50% of the approved home oxygen expenses, to a maximum of $200 per month. Although not explicitly stated in most documents (with the exception of British Columbia, Ontario, Quebec and Nova Scotia), it was assumed that public funding for equipment and allied services was available only for those without any other source of benefits (such as private insurance plans, coverage from Veterans Affairs Canada or the Health Canada's Non-Insured Health Benefits Program (Table 5) . The latter provides home oxygen to eligible registered First Nations and recognized Inuit, when it is not already provided through private insurance plans, provincial or territorial health and social programs, or other publicly funded programs.
In jurisdictions where no home oxygen program exists, oxygen may be obtained from different sources of funding. An example is in the Northwest Territories, where the Department of Health and Social Services has extended health benefit programs that provide full funding support for the purchase or rental of home oxygen, oxygen supplies and equipment. These programs require previous 
DISCUSSION
Our study uncovered heterogeneity in the criteria for eligibility for home oxygen programs and funding across Canada. More importantly, our findings indicate that the available evidence from the current literature does not necessarily translate into the terms of prescription and reimbursement of oxygen in several Canadian jurisdictions. Reimbursement for home oxygen may be quite different from one province to another. Our study also demonstrates that despite the CTS guidelines published in 2007, health care payers maintain their decision to fund, at least in COPD, nocturnal and ambulatory oxygen even if the evidence to support both interventions is lacking. Of course, areas of agreement exist, with only minor differences in the thresholds of prescription for patients with daytime resting hypoxemia and in the definition of pulmonary hypertension and cor pulmonale" when PaO 2 is in the range of 56 mmHg to 59 mmHg. Also, all nine documents support the prescription of nocturnal oxygen; however, with more important differences in the definition of nocturnal desaturation. Areas of disagreement are significantly more common when the indication or practice of oxygen therapy is not clearly evidence based. Examples include the use of oxyhemoglobin saturation as a criterion for funding and the restrictions to the prescription of oxygen to current smokers. The provision of portable cylinders to oxygen-dependent patients or for isolated exercise-induced desaturation and the conditions of reimbursement of oxygen in palliative care are other areas of controversy, although they correspond to issues that have been well addressed in randomized controlled trials and in meta-analyses that demonstrated the limitations of these interventions (12) (13) (14) (15) (16) (17) .
Even if it is expensive and, in several circumstances, of unproven efficacy, why is oxygen so easily reimbursed? One explanation may be that, in addition to being safe and readily available, the prescription of oxygen always makes sense: if oxygen desaturation exists, its correction should help. This reasoning was common before the introduction of 'evidence-based medicine', when the study and understanding of basic mechanisms of disease and pathophysiological principles were considered sufficient to guide clinical practice (18) . However, numerous 
Alberta
Approved if room air SpO 2 <90% at rest during the daytime for at least 3 continuous minutes. "Palliative" must be written on the physician's prescription. The maximum authorization is for six months, and will only be extended for one six-month (maximum) period.
Saskatchewan
The time frame for end-stage care may be measured in terms of days or weeks of active dying.
Eligibility is according to symptoms and performance status (not saturation).
Coverage includes a concentrator and 10 portable oxygen cylinders per month. Funding is for a maximum of four months; only a prescription is required to renew coverage.
Manitoba
Assessment for home oxygen therapy for a palliative care client conforms to the same medical eligibility criteria as those for resting hypoxemia.
Ontario
Funded for individuals who are at the end stage of a terminal illness (ie, life expectancy <3 months), are receiving end-of-life care and require home oxygen therapy.
Funding is provided for a maximum period of 90 days.
Quebec
Palliative oxygen may be considered if severe hypoxemia is present (saturation at rest <88%) in a patient with lung cancer or any other cancer with pulmonary involvement, if vital prognosis is estimated to be <3 months.
For non-neoplastic conditions, palliative oxygen may be considered if severe hypoxemia is present (PaO 2 ≤55 mmHg, or <60 mmHg in case of right heart failure).
New Brunswick For end-stage palliative patients, in whom terminal illness affects the respiratory system; SpO 2 studies confirm oxygen desaturation with SpO 2 <89% on room air.
Nova Scotia
The home oxygen service does not provide funding assistance for home oxygen therapy when prescribed for psychological support of for breathlessness unsupported by evidence of hypoxemia.
Prince Edward Island
Palliative care with a minimum of two oximetry results showing a % saturation <85% and requiring oxygen therapy for at least 18 h per day Clients who are in receipt of home oxygen services and who are determined to be noncompliant with no smoking requirements, will have funding for the service discontinued for a minimum period of 3 months
Patients must certify that "there is no smoking allowed within my home or apartment" examples proved the contrary. For instance, although oxygen corrects oxygen desaturation and improves walked distance in patients with COPD and exercise-induced desaturation in laboratory testing (19) , several trials have failed to demonstrate long-term benefits of this therapy (14) (15) (16) (17) . Terms of reference are not practice guidelines. Nevertheless, in a jurisdiction where medical insurance is universal, they can be assimilated to an insurance contract: they are powerful in delineating medical practice and prescriptions, and have an important financial impact. Funding of effective interventions depends on the maximum costeffectiveness ratio the payer is willing to accept. Funding of interventions that proved ineffective is a waste of money and resources for both the insurer and the policyholders. Funding of interventions of unknown or uncertain efficacy is debatable. This latter situation has at least one pernicious consequence: it is an obvious obstacle to further research. Such has been our own experience with the INOX trial in which recruitment has been stopped after an interim analysis in December 2014. We often faced the reluctance of patients and sometimes clinicians we had invited to participate as coinvestigators to engage into the trial, arguing that nocturnal oxygen therapy is available anyway.
Our study had limitations. It only investigated administrative documents. It did not provide insight into clinical practice and does not inform clinical outcomes. The rigour in the reinforcement of the terms of reference is also unknown. In this regard, the results of a study indicated that, in 2000, 96 of 237 patients (41%) receiving domiciliary oxygen in the Ontario Ministry of Health Home Oxygen Program did not meet criteria for home oxygen (7) . Whether the situation has since improved is unknown. We have no reason to believe that the situation was better elsewhere in the country when this study was conducted.
The results of our study call for action. Most terms of reference defining and governing eligibility to home oxygen equipment, allied services and reimbursement need in-depth revision. In addition to being evidence based, all terms of reference should also be regularly updated. Because health is under provincial jurisdiction in Canada, national terms of reference cannot be created. Closer monitoring of the prescriptions of home oxygen is also mandatory (8) . Accordingly, provincial and national registries of patients on home oxygen should be created. Such registries would be useful in the conduct of clinical and epidemiological research, and to document variations in approaches to the prescription of LTOT. Finally, all efforts to generate evidence regarding the effect of oxygen therapy on survival and quality of life as well as its cost-effectiveness in a variety of conditions and indications must be encouraged. Such efforts are challenging because they require time, money and commitment from the investigators, the clinicians, the patients and their families to bring the clinical trials to their end. However, this investment is certainly worth it for the patients and those who will have to financially support home oxygen therapy. 
